Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

Table 3

Ongoing adjuvant phase III trials evaluating the addition of bevacizumab for the treatment of early breast cancer.

Identifier	Study	𝑁	Study population	Study design
NCT00528567	BEATRICE	2,583	Triple negative BC	Standard CT versus; Standard CT + BEV for 1 year
NCT00887536	NSABP B-46	3,900	HER2 negative; N+ or high risk N−	Docetaxel/cyclophosphamide × 6 versus; Docetaxel/doxorubicin/cyclophosphamide × 6 versus; Docetaxel/cyclophosphamide/BEV × 6; (followed by BEV alone until 1 year)
NCT00625898	BETH	3,509	HER2 positive; N+ or high risk N−	Docetaxel/carboplatin/TRAST × 6; (followed by TRAST alone until 1 year) versus; Docetaxel/carboplatin/TRAST/BEV × 6; (followed by TRAST/BEV until 1 year) versus; Docetaxel [×3]/FEC [×3]/TRAST × 6; (followed by TRAST alone until 1 year) versus; Docetaxel [×3]/FEC [×3]/TRAST/BEV × 6; (followed by TRAST/BEV until 1 year)
NCT00433511	ECOG 5103	4,950	HER2 negative; N+ or high risk N−	AC [×4]/weekly paclitaxel [×12]/placebo versus; AC [×4]/weekly paclitaxel [×12]/BEV versus; AC [×4]/weekly paclitaxel [×12]/BEV; (followed by BEV alone until 1 year)

Identifiers are from clinicaltrials.gov website.
Abbreviations: 𝑛: estimated number of patients; N+: lymph nodes positive; N−: lymph nodes negative; CT: chemotherapy; BEV: bevacizumab; TRAST: trastuzumab; FEC: 5-fluorouracil/epirubicin/cyclophosphamide; AC: adriamycin/cyclophosphamide.